Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOBILE Long-Term Extension: Ibandronate in Postmenopausal Osteoporosis
NCT00081653Phase 4Completed
- Sponsor
- Roche
- Start
- May 2004
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 4, randomised, double-blind trial of ibandronate in postmenopausal osteoporosis (2 arms), sponsored by Roche. Primary endpoints: Absolute Change From Baseline in Mean Lumbar Spine (L2 - L4) BMD at 36 months and Relative Percent (%) Change From Baseline in Mean Lumbar Spine (L2 - L4) Bone Mineral Density (BMD) at 36 months. Started May 2004; status: completed.
02
Drugs
ibandronate
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00081653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081653.